| Literature DB >> 33193225 |
Sujuan Chen1,2,3,4, Keji Quan1, Dandan Wang1, Yinping Du1,2,3, Tao Qin1,2,3,4, Daxin Peng1,2,3,4, Xiufan Liu1,2,3.
Abstract
H5N1 subtype avian influenza virus (AIV) with a deletion of 20 amino acids at residues 49-68 in the stalk region of neuraminidase (NA) became a major epidemic virus. To determine the effect of truncation or deglycosylation of the NA stalk on virulence, we used site-directed mutagenesis to insert 20 amino acids in the short-stalk virus A/mallard/Huadong/S/2005 (SY) to recover the long-stalk virus (rSNA+). A series of short-stalk or deglycosylated-stalk viruses were also constructed basing on the long-stalk virus, and then the characteristics and pathogenicity of the resulting viruses were evaluated. The results showed that most of the short-stalk or deglycosylated-stalk viruses had smaller plaques, and increased thermal and low-pH stability, and a decreased neuraminidase activity when compared with the virus rSNA+. In a mallard ducks challenge study, most of the short-stalk or deglycosylated-stalk viruses showed increased pathological lesions and virus titers in the organ tissues and increased virus shedding in the oropharynx and cloaca when compared with the rSNA+ virus, while most of the short-stalk viruses, especially rSNA-20, showed higher pathogenicity than the deglycosylated-stalk virus. In addition, the short-stalk viruses showed a significantly upregulated expression of the immune-related factors in the lungs of the infected mallard ducks, including IFN-α, Mx1, and IL-8. The results suggested that NA stalk truncation or deglycosylation increases the pathogenicity of H5N1 subtype AIV in mallard ducks, which will provide a pre-warning for prevention and control of H5N1 subtype avian influenza in the waterfowl.Entities:
Keywords: H5N1 subtype AIV; glycosylation; mallard duck; neuraminidase; pathogenicity
Year: 2020 PMID: 33193225 PMCID: PMC7641914 DOI: 10.3389/fmicb.2020.583588
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1SY NA stalks mutant viruses and their western blot analysis. (A) SY and their NA stalk mutant viruses were generated by reverse genetics based on the NA stalk truncation or deglycosylation strategy. (B) Four recombinant viruses with different glycosylation patterns in the stalk of the NA and rSNA+. 1–5: rSNA+, rSNA-Δ50, rSNA-Δ50–Δ58, rSNA-Δ50–Δ58–Δ63, and rSNA-Δ50–Δ58–Δ63–Δ68. (C) Four recombinant viruses with the shortened stalk NA and rSNA+. 1–5: rSNA+, rSNA-5, rSNA-10, rSNA-15, and rSNA-20.
Primers for construction of mutant plasmids of NA genes.
| Target gene | Primer name | Primer sequences (5′ → 3′) |
| Ba-NA-1 | TATT | |
| Ba-NA-2 | ATAT | |
| NA+ | NA+-R | TATGTCTGATTTACCCAGGTGTTGTTTTCATAA GTAATAATGCTTTGATTGCATGGTTCAACTTGG TGTTGATTCCCTGTCTGAATT |
| NA+-F | ACTTATGAAAACAACACCTGGGTAAATCAGAC ATATGTCAACATCAGCAATACTAATTTTCTTAC TGAGAAAGCTGTGGCTT | |
| NA-5 aa | NA-5-R | CATAAGTAATTGGTTCAACTTGGTGTT |
| NA-5-F | CACCAAGTTGAACCAATTACTTATG | |
| NA-10 aa | NA-10-R | TTACCCAGGTGTTTGGTTCAACTTG |
| NA-10-F | ACCAAGTTGAACCAAACACCTG | |
| NA-15 aa | NA-15-R | TATGTCTGTGGTTCAACTTGGTGTT |
| NA-15-F | CACCAAGTTGAACCACAGACATATGTCAAC | |
| NA-Δ50 | 50-F | ATGCAATCAA |
| 50-R | GTAATAAT | |
| NA-Δ58 | 58-F | TGAAAACAAC |
| 58-R | GATTTACCCA | |
| NA-Δ63 | 63-F | CACCTGGGTAAATCAG |
| 63-R | TATTGCTGATGTTGACATA | |
| NA-Δ68 | 68-F | ATGTCAACATC |
| 68-R | TTAGTATT |
Morphometric analysis of histopathological lesion score.
| Group | The degree of the lesion | ||||
| Heart | Brain | Lung | Spleen | Kidney | |
| rSNA-Δ50 | ++++ | ++ | ++ | + | + |
| rSNA-Δ50–Δ58 | ++ | ++ | + | + | + |
| rSNA-Δ50–Δ58–Δ63 | ++ | + | ++ | ++ | + |
| rSNA-Δ50–Δ58–Δ63–Δ68 | + | + | +++ | + | + |
| rSNA+ | + | – | ++ | +++ | + |
| rSNA-5 | ++++ | ++ | +++ | +++ | + |
| rSNA-10 | ++ | ++ | +++ | ++++ | + |
| rSNA-15 | ++++ | ++++ | ++++ | – | + |
| rSNA-20 | ++++ | ++++ | ++++ | +++ | + |
Primers of qRT-PCR for detection of cytokine mRNA level in the lungs of mallard ducks.
| Target gene | Forward primer | Reverse primer |
| GAPDH | ATGTTCGTGATGGGTGTGAA | CTGTCTTCGTGTGTGGCTGT |
| M×1 | TCACACGAAGGCCTATTTTACTGG | GTCGCCGAAGTCATGAAGGA |
| IL-10 | GGGGAGAGGAAACTGAGAGATG | TCACTGGAGGGTAAAATGCAGA |
| IL-1β | GAGATTTTCGAACCCGTCACC | AGGACTGGGAGCGGGTGTA |
| IL-8 | AGGACAACAGAGAGGTGTGCTTG | GCCTTTACGATCCGCTGTACC |
| IL-6 | CTGGCTTCGACGAGGAGAAA | CGTCGTTGCCAGATGCTTTG |
| IFN-α | TTGCTCCTTCCCGGACA | GCTGAGGGTGTCGAAGAGGT |
FIGURE 2Growth curves of recombinant viruses in CEF (A,C) and DEF (B,D) cells. The mean and standard errors are shown from three independent experiments.
FIGURE 3Plaque assay in MDCK cells of recombinant viruses (A). The diameter of 10 independent plaques was measured for each virus sample (B). *P < 0.05, **P < 0.01, compared to the value of the rSNA+.
FIGURE 4Thermal stability of the recombinant viruses at 37°C (A), 42°C (B), and low-pH stability of them (C). *P < 0.05, **P < 0.01, compared to the value of the rSNA+.
FIGURE 5Curves of the recombinant viruses released from the red blood cell surface (A) and neuraminidase activity assays of them (B). *P < 0.05, **P < 0.01, compared to the value of the rSNA+.
Replication of recombinant viruses in the experimentally infected mallard ducks.
| Group | Heart | Spleen | Lung | Kidney | Brain | ||||||||||
| 3 d.p.i. | 5 d.p.i. | 7 d.p.i. | 3 d.p.i.b | 5 d.p.i. | 7 d.p.i. | 3 d.p.i. | 5 d.p.i. | 7 d.p.i. | 3 d.p.i. | 5 d.p.i. | 7 d.p.i. | 3 d.p.i. | 5 d.p.i. | 7 d.p.i. | |
| rSNA-Δ50 | 1/3 (4.0 ± 0)a | 2/3 (3.9 ± 1.0) | 2/3 (2.7 ± 1.0) | 1/3 (4.2 ± 0) | 2/3 (3.1 ± 0.2) | 2/3 (3.7 ± 0.7) | 1/3 (4.7 ± 0) | 2/3 (5.2 ± 0.7) | 3/3 (4.0 ± 1.0) | 1/3 (5.0 ± 0) | 2/3 (4.6 ± 1.2) | 3/3 (3.4 ± 1.1) | 1/3 (4.0 ± 0) | 2/3 (4.1 ± 1.2) | 2/3 (2.7 ± 05) |
| rSNA-Δ50–Δ58 | 2/3 (3.7 ± 0.4) | 2/3 (3.0 ± 0.9) | 0/3 | 2/3 (4.5 ± 0.4) | 3/3 (4.1 ± 0.9) | 0/3 | 2/3 (5.0 ± 0.4) | 3/3 (4.6 ± 1.2) | 0/3 | 2/3 (5.5 ± 0.1) | 3/3 (4.3 ± 0.9) | 0/3 | 1/3 (2.2 ± 0) | 3/3 (3.9 ± 0.9) | 0/3 |
| rSNA-Δ50– Δ58–Δ63 | 3/3 (3.7 ± 0.3) | 2/3 (2.5 ± 0.4) | 0/3 | 3/3 (5.6 ± 0.4) | 2/3 (3.0 ± 1.1) | 0/3 | 3/3 (5.3 ± 0.6) | 3/3 (4.1 ± 0.5) | 0/3 | 3/3 (5.1 ± 0.3) | 2/3 (3.0 ± 1.1) | 1/3 (3 ± 0) | 3/3 (4.1 ± 0.8) | 2/3 (2.5 ± 0.4) | 0/3 |
| rSNA-Δ50– Δ58–Δ63– Δ68 | 3/3 (4.1 ± 0.7) | 3/3 (2.7 ± 0.7) | 0/3 | 3/3 (5.3 ± 0.6) | 2/3 (2.9 ± 0.9) | 0/3 | 3/3 (5.3 ± 0.6) | 2/3 (3.9 ± 1.1) | 1/3 (3 ± 0) | 3/3 (5.6 ± 0.5) | 2/3 (3.5 ± 0.4) | 0/3 | 3/3 (4.3 ± 1.2) | 2/3 (3.5 ± 0.3) | 1/3 (3 ± 0) |
| rSNA+ | 1/3 (3.2 ± 0) | 3/3 (3.4 ± 0.8) | 0/3 | 1/3 (3.5 ± 0) | 2/3 (3.9 ± 0.2) | 0/3 | 2/3 (4.5 ± 0.5) | 2/3 (4.9 ± 0.2) | 0/3 | 1/3 (4.5 ± 0) | 2/3 (4.0 ± 0.4) | 0/3 | 1/3 (4.0 ± 0) | 3/3 (2.9 ± 0.6) | 0/3 |
| rSNA-5 | 2/3 (4.2 ± 1.1) | 3/3 (4.3 ± 0.6) | 0/3 | 1/3 (3.2 ± 0) | 3/3 (4.1 ± 1) | 0/3 | 2/3 (4.7 ± 0) | 3/3 (5.6 ± 0.5) | 0/3 | 1/3 (5.0 ± 0) | 3/3 (4.7 ± 0.7) | 0/3 | 1/3 (4.5 ± 0) | 3/3 (5.3 ± 0.4) | 0/3 |
| rSNA-10 | 3/3 (2.7 ± 0.7) | 2/3 (3.0 ± 0) | 1/3 (3 ± 0) | 3/3 (3.4 ± 0.9) | 2/3 (4.4 ± 0.9) | 1/3 (2.7 ± 0) | 3/3 (4.5 ± 0.4) | 2/3 (5.5 ± 0.5) | 1/3 (3 ± 0) | 3/3 (3.9 ± 0.6) | 2/3 (5.4 ± 0.9) | 2/3 (2.4 ± 0.5) | 3/3 (3.1 ± 0.9) | 2/3 (5.5 ± 0.2) | 1/3 (1.7 ± 0) |
| rSNA-15 | 2/3 (3.6 ± 05) | 2/3 (4.9 ± 0.2) | 0/3 | 3/3 (4.6 ± 0) | 2/3 (4.4 ± 0.5) | 0/3 | 3/3 (4.6 ± 1.2) | 2/3 (6.4 ± 0.9) | 2/3 (2.7 ± 0) | 3/3 (4.7 ± 1.1) | 2/3 (5.7 ± 0) | 0/3 | 2/3 (4.2 ± 1.2) | 3/3 (5.9 ± 0.2) | 0/3 |
| rSNA-20 | 3/3 (4.1 ± 0.1) | 2/3 (5.4 ± 0.5) | 0/3 | 3/3 (4.0 ± 0) | 2/3 (4.2 ± 0.4) | 0/3 | 3/3 (6.0 ± 0) | 2/3 (6.3 ± 0.4) | 1/3 (3 ± 0) | 3/3 (4.5 ± 0.4) | 2/3 (5.1 ± 0.2) | 0/3 | 3/3 (4.6 ± 0.7) | 2/3 (6.0 ± 0.2) | 0/3 |
The viral positive ratio of oropharyngeal and cloacal swabs.
| Group | Oropharyngeal swabs | Cloacal swabs | ||||
| 3 d.p.i. | 5 d.p.i. | 7 d.p.i. | 3 d.p.i. | 5 d.p.i. | 7 d.p.i. | |
| rSNA-Δ50 | 55.6%(5/9)b | 66.7%(4/6) | 0%(0/3) | 22.2%(2/9) | 16.7%(1/6) | 0%(0/3) |
| rSNA-Δ50–Δ58 | 44.4%(4/9) | 66.7%(4/6) | 0%(0/3) | 33.3%(3/9) | 16.7%(1/6) | 0%(0/3) |
| rSNA-Δ50–Δ58–Δ63 | 44.4%(4/9) | 50%(3/6) | 0%(0/3) | 22.2%(2/9) | 16.7%(1/6) | 0%(0/3) |
| rSNA-Δ50–Δ58–Δ63–Δ68 | 88.9%(8/9) | 83.3%(5/6) | 33.3%(1/3) | 44.4%(4/9) | 66.7%(4/6) | 33.3%(1/3) |
| rSNA+ | 44.4%(4/9) | 33.3%(2/6) | 0%(0/3) | 11.1%(1/9) | 16.7%(1/6) | 0%(0/3) |
| rSNA-5 | 77.8%(7/9) | 83.3%(5/6) | 0%(0/3) | 44.4%(4/9) | 50%(3/6) | 0%(0/3) |
| rSNA-10 | 66.7%(6/9) | 66.7%(4/6) | 0%(0/3) | 33.3%(3/9) | 16.7%(1/6) | 0%(0/3) |
| rSNA-15 | 100%(9/9)a | 83.3%(5/6) | 0%(0/3) | 66.7%(6/9)a | 33.3%(2/6) | 0%(0/3) |
| rSNA-20 | 88.9%(8/9) | 66.7%(4/6) | 0%(0/3) | 44.4%(4/9) | 33.3%(2/6) | 0%(0/3) |
FIGURE 6Cytokine response in the lung of the virus-infected mallard ducks. (A) IFN-α, (B) IL-1β, (C) Mx1, (D) IL-6, (E) IL-8, and (F) IL-10. *P < 0.05, **P < 0.01, compared to the value of the rSNA+.